- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03773393
A Clinical Trial of CK0801 (a New Drug) in Patients With Bone Marrow Failure Syndrome (BMF)
Phase I Trial to Evaluate the Safety and Feasibility of CK0801 in Treatment of Bone Marrow Failure Syndrome
The goal of this clinical research study is to determine whether it is safe and practical to give CK0801 (a Cord blood-derived T-regulatory cell product) to patients with bone marrow failure syndrome. Researchers want to determine the highest possible dose that is safe to be given. Researchers also want to learn if CK0801 may improve the symptoms of bone marrow failure syndrome.
Patients enrolled in this study will all have been diagnosed with treatment refractory bone marrow failure syndrome (which includes aplastic anemia, myelodysplastic syndrome, or myelofibrosis). Participants eligible to participate in this study are unable or unwilling to be treated with standard therapy or have failed standard therapy.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Primary Objective:
To determine dose-limiting toxicity of CK0801 as defined as any of the events each start at the time of CK00801 infusion
- Severe (grade 3 or 4) infusion toxicity within 24 hours (NCI-CTCAE V4.0)
- Regimen related death within 30 days
- Severe (grade 3 or 4) Cytokine Release Syndrome within 30 days
Secondary Objective:
- Preliminary assessment of disease-specific response
- Duration of disease-specific response
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
California
-
Santa Monica, California, United States, 90403
- Sarcoma Oncology Research Center, Cancer Center of Southern California
-
-
Texas
-
Houston, Texas, United States, 77030
- The University of Texas Md Anderson Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects who fulfill the diagnostic criteria of bone marrow failure syndrome including: aplastic anemia, myelodysplastic syndrome, or myelofibrosis.
- HLA matched (≥ 3/6) cord blood unit available for CK0801 generation.
- Subjects age ≥ 18 years.
- Bilirubin ≤ 2 x ULN and SGPT (ALT) ≤ 2 x ULN (unless Gilbert's syndrome is documented).
- Calculated creatinine clearance of > 50mL/min using the Cockcroft-Gault equation.
- Zubrod performance status ≤ 2.
- Female subjects of child bearing potential (FPCP) must have a negative urine or serum pregnancy test. NOTE: FPCP is defined as premenopausal and not surgically sterilized. FPCP must agree to use maximally effective birth control or to abstain from heterosexual activity throughout the study. Effective contraceptive methods include intra-uterine device, oral and/or injectable hormonal; contraception, or 2 adequate barrier methods (e.g., cervical cap with spermicide, diaphragm with spermicide).
- Subject has agreed to abide by all protocol required procedures including study-related assessments, visits and long term follow up.
- Subject is willing and able to provide written informed consent.
Exclusion Criteria:
- Subject has received an investigational agent within 4 weeks prior to CK0801 infusion.
- Subject has received radiation or chemotherapy within 21 days prior to CK0801 infusion.
- Subject has received prior cord blood-derived T-regulatory therapy.
- HIV seropositivity.
- Subject has uncontrolled infection, not responding to appropriate antimicrobial agents after seven days of therapy. The Protocol PI is the final arbiter of eligibility.
- Subjects with uncontrolled inter-current illness that in the opinion of the investigator would place the patient at greater risk of severe toxicity and/or impair the activity of CK0801
- Subjects is pregnant or breastfeeding.
- Bone marrow failure caused by stem cell transplantation.
- Subjects who are unable to provide consent or who, in the opinion of the Investigator will be unlikely to fully comply with protocol requirements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CK0801
All subjects will receive adoptive therapy with an infusion of unrelated cord blood-derived regulatory T cells: CK0801.
Subjects will receive one intravenous dose of CK0801 (Treg cells) on study Day 0.
|
CK0801 (a Cord blood-derived T-regulatory cell product)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Severe Infusion Toxicity as Assessed by CTCAE v4.0
Time Frame: 24 hours post-intervention
|
Number of Participants with Severe (Grade 3 or 4) Toxicity
|
24 hours post-intervention
|
Number of Participants with Regimen Related Death
Time Frame: 30 days post-intervention
|
Number of Participants with Regimen Related Death
|
30 days post-intervention
|
Number of Participants with Severe Cytokine Release Syndrome (CRS)
Time Frame: 30 days post-intervention
|
Number of Participants with Severe (Grade 3 or 4) CRS
|
30 days post-intervention
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Tapan M Kadia, MD, The University of Texas Md Anderson Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CK0801-101-1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bone Marrow Disease
-
UNC Lineberger Comprehensive Cancer CenterRecruitingBone Marrow Transplantation | Bone Marrow DiseaseUnited States
-
National Cancer Institute (NCI)RecruitingInherited Bone Marrow Failure Syndrome | Familial Platelet Disorder With Predisposition to Myeloid MalignanciesUnited States
-
Sohag UniversityAssiut University; Kyoto UniversityRecruitingInherited BMF SyndromeEgypt
-
St. Jude Children's Research HospitalTerminatedPain | Bone Marrow DiseaseUnited States
-
Relation TherapeuticsBarts & The London NHS Trust; Royal Free Hospital NHS Foundation Trust; Chelsea... and other collaboratorsRecruitingOsteoarthritis | Bone Diseases | Osteoporosis | Bone Marrow Disease | Bone FractureUnited Kingdom
-
Children's Hospital of PhiladelphiaCompletedBone Marrow Failure Syndromes | Immunodeficiencies | Immune Dysregulation SyndromesUnited States
-
University of California, San FranciscoTerminatedMyeloid Malignancy | Metabolic Disease | Bone Marrow Failure Syndrome | Transfusion-dependent Red Blood Cell (RBC) Defect | Congenital Immunodeficiency | Severe Immune DysregulationUnited States
-
Elixirgen Therapeutics, Inc.Not yet recruiting
-
Children's Hospital of PhiladelphiaAvailableLeukemia | Immunodeficiencies | Bone Marrow Failure SyndromeUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHematologic Diseases | Anemia, Aplastic | Pancytopenia | Blood Disease
Clinical Trials on CK0801
-
Cellenkos, Inc.Withdrawn